FDA cancels Dengvaxia registration,
bans import, distribution, sale

THE Food and Drug Administration (FDA) officially cancelled the product registration of Dengvaxia, the anti-dengue vaccine, which was said to have “aggravated” the rate of immunization in the country.

In an order dated December 21, 2018, a copy of which was released to media on Tuesday, the FDA ordered manufacturer Sanofi Pasteur Inc. to immediately surrender the original certificates of Dengvaxia and Dengvaxia MD, which would prohibit their importation, distribution and sale.